Subscribe To
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance Reaffirms commitment to pursue early market access for Libervant™ (diazepam) Buccal Film Obtains dismissal of outstanding shareholder lawsuits Generated $47 million non-dilutive cash in the last 12 months […] The post Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides...
Read More
Posted: May 2 2023, 20:31
Author Name: forextv
Views: 092158